Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Finished Goods (2022 - 2025)

InMed Pharmaceuticals has reported Finished Goods over the past 4 years, most recently at $378636.0 for Q4 2025.

  • For Q4 2025, Finished Goods fell 43.92% year-over-year to $378636.0; the TTM value through Dec 2025 reached $378636.0, down 43.92%, while the annual FY2025 figure was $676178.0, 19.58% down from the prior year.
  • Finished Goods for Q4 2025 was $378636.0 at InMed Pharmaceuticals, up from $295809.0 in the prior quarter.
  • Over five years, Finished Goods peaked at $927182.0 in Q3 2024 and troughed at $231956.0 in Q1 2025.
  • A 4-year average of $596273.0 and a median of $582161.0 in 2022 define the central range for Finished Goods.
  • Biggest five-year swings in Finished Goods: surged 88.73% in 2023 and later tumbled 68.1% in 2025.
  • Year by year, Finished Goods stood at $605956.0 in 2022, then fell by 7.94% to $557859.0 in 2023, then increased by 21.03% to $675164.0 in 2024, then tumbled by 43.92% to $378636.0 in 2025.
  • Business Quant data shows Finished Goods for INM at $378636.0 in Q4 2025, $295809.0 in Q3 2025, and $676178.0 in Q2 2025.